Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, TimesSquare Capital Management U.S. Small Cap Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"TimesSquare's small-cap growth strategy outperformed in Q3 2023 by focusing on profitable companies with pricing power amid wage inflation and consumer weakness. The manager sold struggling consumer names while adding to medical device companies hurt by GLP-1 sentiment and initiated positions in cloud infrastructure and biotech companies with strong fundamentals and competitive moats."
TimesSquare's U.S. Small Cap Growth strategy outperformed the Russell 2000 Growth Index in Q3 2023, returning -3.67% net versus -7.32% for the benchmark. The manager navigated a challenging environment where value outperformed growth and profitability was the strongest style factor. Key investment dynamics include shrinking labor pools driving wage inflation, renewed engagement with cloud initiatives after earlier spending slowdowns, extreme sentiment around GLP-1 obesity treatments creating opportunities in medical technology, consumer trade-down behavior, and increased industrial infrastructure spending driven by supply chain reassessment and government support. Portfolio activity included selling consumer-focused positions like Leslie's Inc. and Planet Fitness due to fundamental deterioration and management changes, while adding to Treace Medical Concepts on GLP-1 concerns the manager believes are unfounded. New positions were initiated in Krystal Biotech, HashiCorp, and Clearwater Analytics. The strategy maintains its bottom-up approach, focusing on companies with quality management, competitive advantages, and sustainable growth while fine-tuning valuations based on earnings growth and business fundamentals.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager demonstrates high conviction through specific position sizing decisions, detailed company-by-company analysis, and willingness to add to positions during weakness (Treace Medical Concepts) and trim after gains (Hamilton Lane, EMCOR). They name 19 specific holdings with detailed rationales and show conviction in their contrarian views on GLP-1 impact on medical devices.
Growth Outlook
The manager acknowledges challenging market conditions with global equity markets falling in Q3, value outperforming growth, and multiple headwinds including labor cost inflation and consumer weakness. However, they also identify selective opportunities and green shoots in areas like cloud spending and infrastructure investment.
Risk Appetite
The manager demonstrates selective risk-taking by adding to positions like Treace Medical Concepts during weakness and initiating new positions in Krystal Biotech, HashiCorp, and Clearwater Analytics. However, they also sold several consumer-focused positions due to fundamental concerns, showing balanced risk management.
Capital Deployment
The manager shows moderate deployment activity with new positions initiated in three companies (Krystal Biotech, HashiCorp, Clearwater Analytics) and additions to existing positions (Treace Medical Concepts, Allegro MicroSystems). However, they also sold multiple positions and trimmed others, suggesting selective rotation rather than aggressive net deployment.
Forward Guidance
The manager expresses cautious optimism about selective opportunities, particularly in cloud infrastructure and industrial spending, while maintaining their disciplined bottom-up approach. They are actively deploying capital in specific areas but remain selective given market conditions.
Language Signal
The language is balanced with both risk and opportunity language. Risk terms include 'challenges,' 'weakness,' 'concerns,' and 'cautious,' while opportunity language includes 'green shoots,' 'opportunities,' and 'benefits.' The net balance is slightly negative given the emphasis on consumer weakness and market challenges.
Perceived Risk
The manager identifies several meaningful risks including shrinking labor pools with rising costs, consumer spending weakness from higher credit costs and energy prices, and extreme sentiment around GLP-1 treatments. These risks are discussed with specific examples and portfolio implications, indicating moderate risk perception.
Opportunity Density
The manager sees selective opportunities in specific areas like cloud infrastructure, industrial spending, and medical technology stocks hurt by GLP-1 sentiment. However, they express caution about consumer-oriented companies and note that opportunities require selectivity given current market conditions.
Time Horizon
The manager demonstrates a multi-year investment horizon through their fundamental research approach, willingness to hold through short-term volatility, and focus on sustainable competitive advantages. They mention continuous review of business models and valuation models, suggesting a patient capital approach typical of growth investing.
